Share on StockTwits

Enanta Pharmaceuticals (NASDAQ:ENTA) shares reached a new 52-week high during trading on Wednesday , Analyst Ratings reports. The company traded as high as $44.07 and last traded at $43.53, with a volume of 208,366 shares. The stock had previously closed at $41.72.

ENTA has been the subject of a number of recent research reports. Analysts at Macquarie initiated coverage on shares of Enanta Pharmaceuticals in a research note on Tuesday. They set an “outperform” rating and a $18.00 price target on the stock. Analysts at Zacks upgraded shares of Enanta Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 16th. They now have a $43.80 price target on the stock. Four analysts have rated the stock with a buy rating, Enanta Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $40.13.

The stock’s 50-day moving average is $38.14 and its 200-day moving average is $35.76. The company’s market cap is $820.1 million.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings data on Monday, May 12th. The company reported ($0.28) EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.69 by $0.97. The company had revenue of $2.20 million for the quarter, compared to the consensus estimate of $1.20 million. Analysts expect that Enanta Pharmaceuticals will post $0.69 EPS for the current fiscal year.

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.